Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ESMO
Filter by Topic
ESMO 2010 Conference
ESMO 2011 Conference
ESMO 2012 Conference
ESMO 2013 Conference
ESMO 2014 - Gastrointestinal and Head & Neck Cancer
ESMO 2014 - Immuno-Oncology
ESMO 2014 - Prostate Cancer
ESMO 2014 Highlights
ESMO 2016
ESMO 2017 Highlights
ESMO 2018
ESMO 2019
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
By
William King
ESMO
,
Lung Cancer
December 2023, Vol 14, No 6
Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer.
Read Article
Multicancer Early Detection Blood Test May Change Screening Paradigm
By
Phoebe Starr
Cancer Screening
,
ESMO
December 2022, Vol 13, No 6
New results from the PATHFINDER clinical trial suggest that a multicancer early detection blood test can accurately identify the presence of cancer in apparently healthy people. The test, known as Galleri (developed by GRAIL), uses cell-free DNA and machine learning to detect a common cancer signal across more than 50 cancer types as well as to predict cancer signal origin. Once the test is validated and refined further, it may revolutionize the way in which cancer is diagnosed and treated.
Read Article
The Efficacy of Apatinib Treatment for Advanced Ovarian Cancer After Second-Line Chemotherapy Failure
ESMO 2018
,
ESMO
Conference Correspondent
In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals.
Read Article
A Phase 1b and Randomized Phase 2 Trial of Pazopanib with or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
ESMO 2018
,
ESMO
Conference Correspondent
Although the combination of 2 antivascular agents showed preliminary efficacy, increased cardiac toxicity has resulted in premature discontinuation of the trial.
Read Article
Initial Results from an Expansion Cohort Receiving Mirvetuximab Soravtansine/Pembrolizumab for Platinum-Resistant Ovarian Cancer: Initial Results from FORWARD II
ESMO 2018
,
ESMO
Conference Correspondent
The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity.
Read Article
A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
ESMO 2018
,
ESMO
Conference Correspondent
Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early.
Read Article
Maintenance Olaparib Following Platinum-Based Chemotherapy in Newly Diagnosed Patients with Advanced Ovarian Cancer and a BRCA1/2 Mutation: Results from the Phase 3 SOLO1 Trial
ESMO 2018
,
ESMO
Conference Correspondent
Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo.
Read Article
Association of PD-L1 Expression with Clinical Response to Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer
ESMO 2018
,
ESMO
Conference Correspondent
Results from the KEYNOTE-100 study show that expression of PD-L1 and inflamed T-cell–associated genes are associated with clinical response in advanced, recurrent ovarian cancer.
Read Article
Long-Term Tolerability of Olaparib Tablets as Maintenance Therapy for Platinum-Sensitive Relapsed Ovarian Cancer
ESMO 2018
,
ESMO
Conference Correspondent
Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation.
Read Article
Effect of Prior Chemotherapy Regimens on Rucaparib Treatment in Platinum-Sensitive Recurrent Ovarian Carcinoma
ESMO 2018
,
ESMO
Conference Correspondent
Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens.
Read Article
Page 1 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma